Role of protein-protein interactions in cytochrome P450-mediated drug metabolism and toxicity

Chemical Research in Toxicology

Volumn 27, Issue 9, 2014, Pages 1474-1486

  Kandel, Sylvie E ^a   Lampe, Jed N ^b  

^a XenoTech LLC   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; FATTY ACID BINDING PROTEIN 2; HUMAN SERUM ALBUMIN; PROGESTERONE RECEPTOR; SYNAPSIN I; TOXIN; DRUG; ISOPROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SERUM ALBUMIN;

ALLOSTERISM; CHEMICAL STRUCTURE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; DRUG METABOLISM; DRUG TOXICITY; ELECTRON TRANSPORT; ENDOPLASMIC RETICULUM; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; MEMBRANE COMPONENT; METABOLIC ACTIVATION; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; STATIC ELECTRICITY; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; METABOLISM; PROTEIN DOMAIN;

BOVINAE;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; HUMANS; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHARMACEUTICAL PREPARATIONS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; RECEPTORS, PROGESTERONE; SERUM ALBUMIN;

EID: 84918541666     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx500203s     Document Type: Review

References (168)

1. (2005) Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., Ed.) 3rd ed., Kluwer Academic/Plenum Publishers, New York.
2. Lu, A. Y., and Junk., K. W., and Coon, M. J. (1969) Resolution of the cytochrome P-450-containing omega-hydroxylation system of liver microsomes into three components. J. Biol. Chem. 244, 3714-3721.
3. Black, S. D., and French., J. S., Williams, C. H., Jr., and Coon, M. J. (1979) Role of a hydrophobic polypeptide in the N-terminal region of NADPH-cytochrome P-450 reductase in complex formation with P-450LM. Biochem. Biophys. Res. Commun. 91, 1528-1535.
4. Schenkman, J. B., and Jansson, I. (2003) The many roles of cytochrome b5. Pharmacol. Ther. 97, 139-152.
5. Lu, A. Y., and Coon, M. J. (1968) Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble enzyme system from liver microsomes. J. Biol. Chem. 243, 1331-1332.
6. Sugishima, M., Sato, H., Higashimoto, Y., Harada, J., Wada, K., Fukuyama, K. Noguchi, M. (2014) Structural basis for the electron transfer from an open form of NADPH-cytochrome P450 oxidoreductase to heme oxygenase. Proc. Natl. Acad. Sci. U.S.A. 111, 2524-2529.
7. Yamazaki, H., Shimada, T., Martin, M. V., and Guengerich, F. P. (2001) Stimulation of cytochrome P450 reactions by apo-cytochrome b5: evidence against transfer of heme from cytochrome P450 3A4 to apo-cytochrome b5 or heme oxygenase. J. Biol. Chem. 276, 30885-30891.
8. Laden, B. P., Tang, Y., and Porter, T. D. (2000) Cloning, heterologous expression, and enzymological characterization of human squalene monooxygenase. Arch. Biochem. Biophys. 374, 381-388.
9. Laguna, J. C., and Nagi., M. N., Cook, L., and Cinti, D. L. (1989) Action of ebselen on rat hepatic microsomal enzyme-catalyzed fatty acid chain elongation, desaturation, and drug biotransformation. Arch. Biochem. Biophys. 269, 272-283.
10. Wang, M., and Roberts., D. L., Paschke, R., Shea, T. M., Masters, B. S., and Kim, J. J. (1997) Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc. Natl. Acad. Sci. U.S.A. 94, 8411-8416.
11. Sevrioukova, I. F., Li, H., Zhang, H., Peterson, J. A., and Poulos, T. L. (1999) Structure of a cytochrome P450-redox partner electron-transfer complex. Proc. Natl. Acad. Sci. U.S.A. 96, 1863-1868.
12. Iyanagi, T., and Mason, H. S. (1973) Some properties of hepatic reduced nicotinamide adenine dinucleotide phosphate-cytochrome c reductase. Biochemistry 12, 2297-2308.
13. Yasukochi, Y., and Masters, B. S. (1976) Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. Chem. 251, 5337-5344.
14. Strobel, H. W., and Nadler., S. G., and Nelson, D. R. (1989) Cytochrome P-450: cytochrome P-450 reductase interactions. Drug Metab. Rev. 20, 519-533.
15. Bhattacharyya, A. K., and Hurley., J. K., Tollin, G., and Waskell, L. (1994) Investigation of the rate limiting step for electron transfer from NADPH: cytochrome P450 reductase to cytochrome b5: a laser flash-photolysis study. Arch. Biochem. Biophys. 310, 318-324.
16. Djordjevic, S., and Roberts., D. L., Wang, M., Shea, T., Camitta, M. G., Masters, B. S., and Kim, J. J. (1995) Crystallization and preliminary X-ray studies of NADPH-cytochrome P450 reductase. Proc. Natl. Acad. Sci. U.S.A 92, 3214-3218.
17. Roman, L. J., McLain, J., and Masters, B. S. (2003) Chimeric enzymes of cytochrome P450 oxidoreductase and neuronal nitric-oxide synthase reductase domain reveal structural and functional differences. J. Biol. Chem. 278, 25700-25707.
18. Hamdane, D., Xia, C., Im, S. C., Zhang, H., Kim, J. J., and Waskell, L. (2009) Structure and function of an NADPH-cytochrome P450 oxidoreductase in an open conformation capable of reducing cytochrome P450. J. Biol. Chem. 284, 11374-11384.
19. Ellis, J., Gutierrez, A., Barsukov, I. L., Huang, W. C., Grossmann, J. G., and Roberts, G. C. (2009) Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle X-ray scattering. J. Biol. Chem. 284, 36628-36637.
20. Jenner, M., Ellis, J., Huang, W. C., Lloyd Raven, E., Roberts, G. C., and Oldham, N. J. (2011) Detection of a protein conformational equilibrium by electrospray ionisation-ion mobility-mass spectrometry. Angew. Chem., Int. Ed. 50, 8291-8294.
21. Vincent, B., Morellet, N., Fatemi, F., Aigrain, L., Truan, G., Guittet, E. Lescop, E. (2012) The closed and compact domain organization of the 70-kDa human cytochrome P450 reductase in its oxidized state as revealed by NMR. J. Mol. Biol. 420, 296-309.
22. Laursen, T., Singha, A., Rantzau, N., Tutkus, M., Borch, J., Hedegård, P., Stamou, D., Møller, B. L. Hatzakis, N. S. (2014) Single molecule activity measurements of cytochrome P450 oxidoreductase reveal the existence of two discrete functional states. ACS Chem. Biol. 9, 630-634.
23. Sundermann, A. Oostenbrink, C. (2013) Molecular dynamics simulations give insight into the conformational change, complex formation, and electron transfer pathway for cytochrome P450 reductase. Protein Sci. 22, 1183-1195.
24. Xia, C., Hamdane, D., Shen, A. L., Choi, V., Kasper, C. B., Pearl, N. M., Zhang, H., Im, S. C., Waskell, L., and Kim, J. J. (2011) Conformational changes of NADPH-cytochrome P450 oxidoreductase are essential for catalysis and cofactor binding. J. Biol. Chem. 286, 16246-16260.
25. Gao, Q., and Doneanu., C. E., Shaffer, S. A., Adman, E. T., Goodlett, D. R., and Nelson, S. D. (2006) Identification of the interactions between cytochrome P450 2E1 and cytochrome b5 by mass spectrometry and site-directed mutagenesis. J. Biol. Chem. 281, 20404-20417.
26. Zhang, W., Liu, Y., Yan, J., Cao, S., Bai, F., Yang, Y., Huang, S., Yao, L., Anzai, Y., Kato, F., and Podust., L. M., Sherman, D. H., and Li, S. (2014) New reactions and products resulting from alternative interactions between the P450 enzyme and redox partners. J. Am. Chem. Soc. 136, 3640-3646.
27. Narayanasami, R., and Horowitz., P. M., and Masters, B. S. (1995) Flavin-binding and protein structural integrity studies on NADPH-cytochrome P450 reductase are consistent with the presence of distinct domains. Arch. Biochem. Biophys. 316, 267-274.
28. Kim, J. J., and Roberts., D. L., Djordjevic, S., Wang, M., Shea, T. M., and Masters, B. S. (1996) Crystallization studies of NADPH-cytochrome P450 reductase. Methods Enzymol. 272, 368-377.
29. Kranendonk, M., and Marohnic., C. C., Panda, S. P., Duarte, M. P., Oliveira, J. S., Masters, B. S., and Rueff, J. (2008) Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch. Biochem. Biophys. 475, 93-99.
30. Moutinho, D., and Marohnic., C. C., Panda, S. P., Rueff, J., Masters, B. S., and Kranendonk, M. (2012) Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system. Drug Metab. Dispos. 40, 754-760.
31. Marohnic, C. C., and Panda., S. P., McCammon, K., Rueff, J., Masters, B. S., and Kranendonk, M. (2010) Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab. Dispos. 38, 332-340.
32. Fluck, C. E., and Mullis., P. E., and Pandey, A. V. (2010) Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochem. Biophys. Res. Commun. 401, 149-153.
33. Pandey, A. V., and Fluck, C. E. (2013) NADPH P450 oxidoreductase: structure, function, and pathology of diseases. Pharmacol. Ther. 138, 229-254.
34. Reed, J. R., and Cawley., G. F., and Backes, W. L. (2011) Inhibition of cytochrome P450 1A2-mediated metabolism and production of reactive oxygen species by heme oxygenase-1 in rat liver microsomes. Drug Metab. Lett. 5, 6-16.
35. Peterson, J. A., and Ebel., R. E., O'Keeffe, D. H., Matsubara, T., and Estabrook, R. W. (1976) Temperature dependence of cytochrome P-450 reduction. A model for NADPH-cytochrome P-450 reductase:-cytochrome P-450 interaction. J. Biol. Chem. 251, 4010-4016.
36. Estabrook, R. W., and Hildebrandt., A. G., Baron, J., Netter, K. J., and Leibman, K. (1971) A new spectral intermediate associated with cytochrome P-450 function in liver microsomes. Biochem. Biophys. Res. Commun. 42, 132-139.
37. Bridges, A., Gruenke, L., Chang, Y. T., Vakser, I. A., Loew, G., and Waskell, L. (1998) Identification of the binding site on cytochrome P450 2B4 for cytochrome b5 and cytochrome P450 reductase. J. Biol. Chem. 273, 17036-17049.
38. Shen, S., and Strobel, H. W. (1993) Role of lysine and arginine residues of cytochrome P450 in the interaction between cytochrome P4502B1 and NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 304, 257-265.
39. Shimizu, T., Tateishi, T., Hatano, M., and Fujii-Kuriyama, Y. (1991) Probing the role of lysines and arginines in the catalytic function of cytochrome P450d by site-directed mutagenesis. Interaction with NADPH-cytochrome P450 reductase. J. Biol. Chem. 266, 3372-3375.
40. Kenaan, C., Zhang, H., Shea, E. V., and Hollenberg, P. F. (2011) Uncovering the role of hydrophobic residues in cytochrome P450-cytochrome P450 reductase interactions. Biochemistry 50, 3957-3967.
41. Voznesensky, A. I., and Schenkman, J. B. (1992) The cytochrome P450 2B4-NADPH cytochrome P450 reductase electron transfer complex is not formed by charge-pairing. J. Biol. Chem. 267, 14669-14676.
42. Shimada, T., and Mernaugh., R. L., and Guengerich, F. P. (2005) Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes. Arch. Biochem. Biophys. 435, 207-216.
43. French, J. S., and Guengerich., F. P., and Coon, M. J. (1980) Interactions of cytochrome P-450, NADPH-cytochrome P-450 reductase, phospholipid, and substrate in the reconstituted liver microsomal enzyme system. J. Biol. Chem. 255, 4112-4119.
44. Estrada, D. F., and Laurence., J. S., and Scott, E. E. (2013) Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR. J. Biol. Chem. 288, 17008-17018.
45. Hiruma, Y., and Hass., M. A., Kikui, Y., Liu, W. M., Olmez, B., Skinner, S. P., Blok, A., Kloosterman, A., Koteishi, H., Lohr, F., Schwalbe, H., Nojiri, M., and Ubbink, M. (2013) The structure of the cytochrome p450cam-putidaredoxin complex determined by paramagnetic NMR spectroscopy and crystallography. J. Mol. Biol. 425, 4353-4365.
46. Pochapsky, S. S., and Pochapsky., T. C., and Wei, J. W. (2003) A model for effector activity in a highly specific biological electron transfer complex: the cytochrome P450(cam)-putidaredoxin couple. Biochemistry 42, 5649-5656.
47. OuYang, B., and Pochapsky., S. S., Dang, M., and Pochapsky, T. C. (2008) A functional proline switch in cytochrome P450cam. Structure 16, 916-923.
48. Pochapsky, S. S., Dang, M., OuYang, B., Simorellis, A. K., and Pochapsky, T. C. (2009) Redox-dependent dynamics in cytochrome P450cam. Biochemistry 48, 4254-4261.
49. Huang, N., Agrawal, V., Giacomini, K. M., and Miller, W. L. (2008) Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc. Natl. Acad. Sci. U.S.A. 105, 1733-1738.
50. Huang, N., and Pandey., A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Van Vliet, G., Sack, J., Fluck, C. E., and Miller, W. L. (2005) Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet. 76, 729-749.
51. Agrawal, V., Huang, N., and Miller, W. L. (2008) Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genomics 18, 569-576.
52. Sandee, D., Morrissey, K., Agrawal, V., Tam, H. K., Kramer, M. A., Tracy, T. S., Giacomini, K. M., and Miller, W. L. (2010) Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet. Genomics 20, 677-686.
53. Davydov, D. R., and Halpert, J. R. (2008) Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both? Expert Opin. Drug Metab. Toxicol. 4, 1523-1535.
54. Atkins, W. M. (2006) Current views on the fundamental mechanisms of cytochrome P450 allosterism. Expert Opin. Drug Metab. Toxicol. 2, 573-579.
55. Agrawal, V., and Choi., J. H., Giacomini, K. M., and Miller, W. L. (2010) Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet. Genomics 20, 611-618.
56. Chen, X., and Pan., L. Q., Naranmandura, H., Zeng, S., and Chen, S. Q. (2012) Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6. PLoS One 7, e38495.
57. Hayashi, S., Omata, Y., Sakamoto, H., Hara, T., and Noguchi, M. (2003) Purification and characterization of a soluble form of rat liver NADPH-cytochrome P-450 reductase highly expressed in Escherichia coli. Protein Expression Purif. 29, 1-7.
58. Lamb, D. C., Kim, Y., Yermalitskaya, L. V., Yermalitsky, V. N., Lepesheva, G. I., Kelly, S. L., Waterman, M. R., and Podust, L. M. (2006) A second FMN binding site in yeast NADPH-cytochrome P450 reductase suggests a mechanism of electron transfer by diflavin reductases. Structure 14, 51-61.
59. Hubbard, P. A., and Shen., A. L., Paschke, R., Kasper, C. B., and Kim, J. J. (2001) NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J. Biol. Chem. 276, 29163-29170.
60. Subramanian, M., Agrawal, V., Sandee, D., Tam, H. K., Miller, W. L., and Tracy, T. S. (2012) Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet. Genomics 22, 590-597.
61. Han, J. F., and Wang., S. L., He, X. Y., Liu, C. Y., and Hong, J. Y. (2006) Effect of genetic variation on human cytochrome p450 reductase-mediated paraquat cytotoxicity. Toxicol. Sci. 91, 42-48.
62. Wang, S. L., and Han., J. F., He, X. Y., Wang, X. R., and Hong, J. Y. (2007) Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity. Drug Metab. Dispos. 35, 176-179.
63. Iyanagi, T., Xia, C., and Kim, J. J. (2012) NADPH-cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family. Arch. Biochem. Biophys. 528, 72-89.
64. Fussell, K. C., and Udasin., R. G., Gray, J. P., Mishin, V., Smith, P. J., Heck, D. E., and Laskin, J. D. (2011) Redox cycling and increased oxygen utilization contribute to diquat-induced oxidative stress and cytotoxicity in Chinese hamster ovary cells overexpressing NADPH-cytochrome P450 reductase. Free Radical Biol. Med. 50, 874-882.
65. Seow, H. A., and Penketh., P. G., Baumann, R. P., and Sartorelli, A. C. (2004) Bioactivation and resistance to mitomycin C. Methods Enzymol. 382, 221-233.
66. ∗28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenom-ics 12, 1281-1291.
67. Zhang, X., Li, L., Ding, X., and Kaminsky, L. S. (2011) Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab. Dispos. 39, 1433-1439.
68. Im, S. C., and Waskell, L. (2011) The interaction of microsomal cytochrome P450 2B4 with its redox partners, cytochrome P450 reductase and cytochrome b(5). Arch. Biochem. Biophys. 507, 144-153.
69. Vergeres, G., and Waskell, L. (1995) Cytochrome b5, its functions, structure and membrane topology. Biochimie 77, 604-620.
70. Sanborn, R. C., and Williams, C. M. (1950) The cytochrome system in the cecropia silkworm, with special reference to the properties of a new component. J. Gen. Physiol. 33, 579-588.
71. Hegesh, E., Hegesh, J., and Kaftory, A. (1986) Congenital methemoglobinemia with a deficiency of cytochrome b5. N. Engl. J. Med. 314, 757-761.
72. Kok, R. C., and Timmerman., M. A., Wolffenbuttel, K. P., Drop, S. L. de Jong, F. H. (2010) Isolated 17, 20-lyase deficiency due to the cytochrome b5 mutation W27X. J. Clin. Endocrinol. Metab. 95, 994-999.
73. Idkowiak, J., Randell, T., Dhir, V., Patel, P., and Shackleton., C. H., Taylor, N. F., Krone, N., and Arlt, W. (2012) A missense mutation in the human cytochrome b5 gene causes 46, XY disorder of sex development due to true isolated 17, 20 lyase deficiency. J. Clin. Endocrinol. Metab. 97, E465-475.
74. Hildebrandt, A., and Estabrook, R. W. (1971) Evidence for the participation of cytochrome b 5 in hepatic microsomal mixed-function oxidation reactions. Arch. Biochem. Biophys. 143, 66-79.
75. Correia, M. A., and Mannering, G. J. (1973) Reduced diphosphopyridine nucleotide synergism of the reduced triphospho-pyridine nucleotide-dependent mixed-function oxidase system of hepatic microsomes. I. Effects of activation and inhibition of the fatty acyl coenzyme A desaturation system. Mol. Pharmacol. 9, 455-469.
76. Henderson, C. J., and McLaughlin., L. A., and Wolf, C. R. (2013) Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system. Mol. Pharmacol. 83, 1209-1217.
77. Peng, H. M., and Auchus, R. J. (2014) Two surfaces of cytochrome b5 with major and minor contributions to CYP3A4-catalyzed steroid and nifedipine oxygenation chemistries. Arch. Biochem. Biophys. 541, 53-60.
78. Finn, R. D., and McLaughlin., L. A., Ronseaux, S., Rosewell, I., Houston, J. B., Henderson, C. J., and Wolf, C. R. (2008) Defining the in vivo role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5. J. Biol. Chem. 283, 31385-31393.
79. Lin, H. L., and Hollenberg, P. F. (2007) The inactivation of cytochrome P450 3A5 by 17α-ethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. J. Pharmacol. Exp. Ther. 321, 276-287.
80. Reed, J. R., and Hollenberg, P. F. (2003) Examining the mechanism of stimulation of cytochrome P450 by cytochrome b5: the effect of cytochrome b5 on the interaction between cytochrome P450 2B4 and P450 reductase. J. Inorg. Biochem. 97, 265-275.
81. Gruenke, L. D., Konopka, K., Cadieu, M., and Waskell, L. (1995) The stoichiometry of the cytochrome P-450-catalyzed metabolism of methoxyflurane and benzphetamine in the presence and absence of cytochrome b5. J. Biol. Chem. 270, 24707-24718.
82. Morgan, E. T., and Coon, M. J. (1984) Effects of cytochrome b5 on cytochrome P-450-catalyzed reactions. Studies with manganese-substituted cytochrome b5. Drug Metab. Dispos. 12, 358-364.
83. Yamazaki, H., Nakamura, M., Komatsu, T., Ohyama, K., Hatanaka, N., Asahi, S., Shimada, N., and Guengerich., F. P., Shimada, T., Nakajima, M., and Yokoi, T. (2002) Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expression Purif. 24, 329-337.
84. Yamazaki, H., Nakano, M., Imai, Y., Ueng, Y. F., Guengerich, F. P., and Shimada, T. (1996) Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Arch. Biochem. Biophys. 325, 174-182.
85. Soucy, P., and Luu-The, V. (2002) Assessment of the ability of type 2 cytochrome b5 to modulate 17, 20-lyase activity of human P450c17. J. Steroid Biochem. Mol. Biol. 80, 71-75.
86. Yamazaki, H., and Johnson., W. W., Ueng, Y. F., Shimada, T., and Guengerich, F. P. (1996) Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5. J. Biol. Chem. 271, 27438-27444.
87. Yamazaki, H., and Gillam., E. M., Dong, M. S., Johnson, W. W., Guengerich, F. P., and Shimada, T. (1997) Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Arch. Biochem. Biophys. 342, 329-337.
88. Auchus, R. J., and Lee., T. C., and Miller, W. L. (1998) Cytochrome b5 augments the 17, 20-lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 273, 3158-3165.
89. Lee-Robichaud, P., Akhtar, M. E., and Wright., J. N., Sheikh, Q. I., and Akhtar, M. (2004) The cationic charges on Arg347, Arg358 and Arg449 of human cytochrome P450c17 (CYP17) are essential for the enzyme's cytochrome b5-dependent acyl-carbon cleavage activities. J. Steroid Biochem. Mol. Biol. 92, 119-130.
90. Bell, L. C., and Guengerich, F. P. (1997) Oxidation kinetics of ethanol by human cytochrome P450 2E1. Rate-limiting product release accounts for effects of isotopic hydrogen substitution and cytochrome b5 on steady-state kinetics. J. Biol. Chem. 272, 29643-29651.
91. Kumar, S., and Davydov., D. R., and Halpert, J. R. (2005) Role of cytochrome B5 in modulating peroxide-supported cyp3a4 activity: evidence for a conformational transition and cytochrome P450 heterogeneity. Drug Metab. Dispos. 33, 1131-1136.
92. Schenkman, J. B., and Voznesensky., A. I., and Jansson, I. (1994) Influence of ionic strength on the P450 monooxygenase reaction and role of cytochrome b5 in the process. Arch. Biochem. Biophys. 314, 234-241.
93. Perret, A., and Pompon, D. (1998) Electron shuttle between membrane-bound cytochrome P450 3A4 and b5 rules uncoupling mechanisms. Biochemistry 37, 11412-11424.
94. Ahuja, S., Jahr, N., Im, S. C., Vivekanandan, S., Popovych, N., Le Clair, S. V., Huang, R., Soong, R., Xu, J., Yamamoto, K., Nanga, R. P., Bridges, A., Waskell, L., and Ramamoorthy, A. (2013) A model of the membrane-bound cytochrome b5-cytochrome P450 complex from NMR and mutagenesis data. J. Biol. Chem. 288, 22080-22095.
95. Zhang, H., Hamdane, D., Im, S. C., and Waskell, L. (2008) Cytochrome b5 inhibits electron transfer from NADPH-cytochrome P450 reductase to ferric cytochrome P450 2B4. J. Biol. Chem. 283, 5217-5225.
96. Omata, Y., and Robinson., R. C., Gelboin, H. V., Pincus, M. R., and Friedman, F. K. (1994) Specificity of the cytochrome P-450 interaction with cytochrome b5. FEBS Lett. 346, 241-245.
97. Stayton, P. S., and Sligar, S. G. (1990) The cytochrome P-450cam binding surface as defined by site-directed mutagenesis and electrostatic modeling. Biochemistry 29, 7381-7386.
98. Soong, R., and Smith., P. E., Xu, J., Yamamoto, K., Im, S. C., Waskell, L., and Ramamoorthy, A. (2010) Proton-evolved local-field solid-state NMR studies of cytochrome b5 embedded in bicelles, revealing both structural and dynamical information. J. Am. Chem. Soc. 132, 5779-5788.
99. Lin, Y. W., and Wang, J. (2013) Structure and function of heme proteins in non-native states: a mini-review. J. Inorg. Biochem. 129, 162-171.
100. Xu, J., Soong, R., Im, S. C., Waskell, L., and Ramamoorthy, A. (2010) INEPT-based separated-local-field NMR spectroscopy: a unique approach to elucidate side-chain dynamics of membrane-associated proteins. J. Am. Chem. Soc. 132, 9944-9947.
101. Katagiri, M., Suhara, K., Shiroo, M., and Fujimura, Y. (1982) Role of cytochrome b5 in the cytochrome P-450-mediated C21-steroid 17, 20-lyase reaction. Biochem. Biophys. Res. Commun. 108, 379-384.
102. Onoda, M., and Hall, P. F. (1982) Cytochrome b5 stimulates purified testicular microsomal cytochrome P-450 (C21 side-chain cleavage). Biochem. Biophys. Res. Commun. 108, 454-460.
103. Estrada, D. F., and Skinner., A. L., Laurence, J. S., and Scott, E. E. (2014) Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5. J. Biol. Chem. 289, 14310-14320.
104. Yamamoto, K., and Durr., U. H., Xu, J., Im, S. C., Waskell, L., and Ramamoorthy, A. (2013) Dynamic interaction between membrane-bound full-length cytochrome P450 and cytochrome b5 observed by solid-state NMR spectroscopy. Sci. Rep. 3, 2538.
105. 15N resonance assignments for the full-length mammalian cytochrome b in a membrane environment. Biomol. NMR Assignments, DOI: 10.1007/s12104-013-9528-9.
106. 15N chemical shift anisotropy from a membrane-bound protein by NMR spectroscopy. J. Phys. Chem. B 116, 7181-7189.
107. Henderson, C. J., and McLaughlin., L. A., Finn, R. D., Ronseaux, S., Kapelyukh, Y., and Wolf, C. R. (2014) A role for cytochrome b5 in the in vivo disposition of anticancer and cytochrome P450 probe drugs in mice. Drug Metab. Dispos. 42, 70-77.
108. Locuson, C. W., and Wienkers., L. C., Jones, J. P., and Tracy, T. S. (2007) CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis. Drug Metab. Dispos. 35, 1174-1181.
109. Borthiry, G. R., and Antholine., W. E., Kalyanaraman, B., Myers, J. M., and Myers, C. R. (2007) Reduction of hexavalent chromium by human cytochrome b5: generation of hydroxyl radical and superoxide. Free Radical Biol. Med. 42, 738-755.
110. Borthiry, G. R., and Antholine., W. E., Myers, J. M., and Myers, C. R. (2008) Addition of DNA to Cr(VI) and cytochrome b5 containing proteoliposomes leads to generation of DNA strand breaks and Cr(III) complexes. Chem. Biodiversity 5, 1545-1557.
111. Dmitriev, L. F. (2007) The involvement of lipid radical cycles and the adenine nucleotide translocator in neurodegenerative diseases. J. Alzheimer's Dis. 11, 183-190.
112. Davydov, D. R., Deprez, E., Hoa, G. H., Knyushko, T. V., Kuznetsova, G. P., Koen, Y. M., and Archakov, A. I. (1995) High-pressure-induced transitions in microsomal cytochrome P450 2B4 in solution: evidence for conformational inhomogeneity in the oligomers. Arch. Biochem. Biophys. 320, 330-344.
113. Davydov, D. R., and Knyushko., T. V., and Hoa, G. H. (1992) High pressure induced inactivation of ferrous cytochrome P-450 LM2 (IIB4) CO complex: evidence for the presence of two conformers in the oligomer. Biochem. Biophys. Res. Commun. 188, 216-221.
114. 2+) as a competitive inhibitor of NADPH-dependent reduction of cytochrome P450 LM2: locating proteinprotein interaction sites in microsomal electron carriers. Arch. Biochem. Biophys. 297, 304-313.
115. Schwarz, D., Pirrwitz, J., Meyer, H. W., Coon, M. J., and Ruckpaul, K. (1990) Membrane topology of microsomal cytochrome P-450: saturation transfer EPR and freeze-fracture electron microscopy studies. Biochem. Biophys. Res. Commun. 171, 175-181.
116. Myasoedova, K. N., and Berndt, P. (1990) Cytochrome P-450LM2 oligomers in proteoliposomes. FEBS Lett. 275, 235-238.
117. Reed, J. R., and Connick., J. P., Cheng, D., Cawley, G. F., and Backes, W. L. (2012) Effect of homomeric P450-P450 complexes on P450 function. Biochem. J. 446, 489-497.
118. Davydov, D. R. (2011) Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions. Expert Opin. Drug Metab. Toxicol. 7, 543-558.
119. Cawley, G. F., Zhang, S., Kelley, R. W., and Backes, W. L. (2001) Evidence supporting the interaction of CYP2B4 and CYP1A2 in microsomal preparations. Drug Metab. Dispos. 29, 1529-1534.
120. Backes, W. L., and Batie., C. J., and Cawley, G. F. (1998) Interactions among P450 enzymes when combined in reconstituted systems: formation of a 2B4-1A2 complex with a high affinity for NADPH-cytochrome P450 reductase. Biochemistry 37, 12852-12859.
121. Cawley, G. F., and Batie., C. J., and Backes, W. L. (1995) Substrate-dependent competition of different P450 isozymes for limiting NADPH-cytochrome P450 reductase. Biochemistry 34, 1244-1247.
122. Alston, K., and Robinson., R. C., Park, S. S., Gelboin, H. V., and Friedman, F. K. (1991) Interactions among cytochromes P-450 in the endoplasmic reticulum. Detection of chemically cross-linked complexes with monoclonal antibodies. J. Biol. Chem. 266, 735-739.
123. Davydov, D. R., Fernando, H., Baas, B. J., Sligar, S. G., and Halpert, J. R. (2005) Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry 44, 13902-13913.
124. Szczesna-Skorupa, E., Mallah, B., and Kemper, B. (2003) Fluorescence resonance energy transfer analysis of cytochromes P450 2C2 and 2E1 molecular interactions in living cells. J. Biol. Chem. 278, 31269-31276.
125. Li, B., Yau, P., and Kemper, B. (2011) Identification of cytochrome P450 2C2 protein complexes in mouse liver. Proteomics 11, 3359-3368.
126. Jamakhandi, A. P., Kuzmic, P., Sanders, D. E., and Miller, G. P. (2007) Global analysis of protein-protein interactions reveals multiple CYP2E1-reductase complexes. Biochemistry 46, 10192-10201.
127. Reed, J. R., and Backes, W. L. (2012) Formation of P450. P450 complexes and their effect on P450 function. Pharmacol. Ther. 133, 299-310.
128. Seibert, E., and Tracy, T. S. (2014) Different enzyme kinetic models. Methods Mol. Biol. 1113, 23-35.
129. Davydov, D. R., and Davydova., N. Y., Sineva, E. V., Kufareva, I., and Halpert, J. R. (2013) Pivotal role of P450-P450 interactions in CYP3A4 allostery: the case of alpha-naphthoflavone. Biochem. J. 453, 219-230.
130. Atkins, W. M., and Lu., W. D., and Cook, D. L. (2002) Is there a toxicological advantage for non-hyperbolic kinetics in cytochrome P450 catalysis? Functional allostery from "distributive catalysis". J. Biol. Chem. 277, 33258-33266.
131. Ozalp, C., Szczesna-Skorupa, E., and Kemper, B. (2005) Bimolecular fluorescence complementation analysis of cytochrome p450 2c2, 2e1, and NADPH-cytochrome p450 reductase molecular interactions in living cells. Drug Metab. Dispos. 33, 1382-1390.
132. Hazai, E., and Kupfer, D. (2005) Interactions between CYP2C9 and CYP2C19 in reconstituted binary systems influence their catalytic activity: possible rationale for the inability of CYP2C19 to catalyze methoxychlor demethylation in human liver microsomes. Drug Metab. Dispos. 33, 157-164.
133. Hu, Y., and Kupfer, D. (2002) Metabolism of the endocrine disruptor pesticide-methoxychlor by human P450s: pathways involving a novel catechol metabolite. Drug Metab. Dispos. 30, 1035-1042.
134. Hu, Y., Krausz, K., Gelboin, H. V., and Kupfer, D. (2004) CYP2C subfamily, primarily CYP2C9, catalyses the enantioselective demethylation of the endocrine disruptor pesticide methoxychlor in human liver microsomes: use of inhibitory monoclonal antibodies in P450 identification. Xenobiotica 34, 117-132.
135. Hazai, E., Bikadi, Z., Simonyi, M., and Kupfer, D. (2005) Association of cytochrome P450 enzymes is a determining factor in their catalytic activity. J. Comput.-Aided Mol. Des. 19, 271-285.
136. Subramanian, M., Low, M., Locuson, C. W., and Tracy, T. S. (2009) CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab. Dispos. 37, 1682-1689.
137. Backes, W. L., and Sligar., S. G., and Schenkman, J. B. (1982) Kinetics of hepatic cytochrome P-450 reduction: correlation with spin state of the ferric heme. Biochemistry 21, 1324-1330.
138. Reed, J. R, Eyer, M., and Backes, W. L. (2010) Functional interactions between cytochromes P450 1A2 and 2B4 require both enzymes to reside in the same phospholipid vesicle: evidence for physical complex formation. J. Biol. Chem. 285, 8942-8952.
139. Subramanian, M., Tam, H., Zheng, H., and Tracy, T. S. (2010) CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab. Dispos. 38, 1003-1009.
140. Hughes, A. L., and Powell., D. W., Bard, M., Eckstein, J., Barbuch, R, Link, A J., and Espenshade, P. J. (2007) Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 5, 143-149.
141. Yamasaki, K., and Chuang., V. T., Maruyama, T., and Otagiri, M. (2013) Albumin - drug interaction and its clinical implication. Biochim. Biophys. Acta 1830, 5435-5443.
142. Min, L., and Strushkevich., N. V., Harnastai, I. N, Iwamoto, H., and Gilep., A. A., Takemori, H., Usanov, S. A., Nonaka, Y., Hori, H., Vinson, G P., and Okamoto, M. (2005) Molecular identification of adrenal inner zone antigen as a heme-binding protein. FEBS J. 272, 5832-5843.
143. Mifsud, W., and Bateman, A (2002) Membrane-bound progesterone receptors contain a cytochrome b5-like ligand-binding domain. Genome Biol. 3, No. research0068.
144. Peluso, J. J., Liu, X., Saunders, M. M., Claffey, K. P., and Phoenix, K. (2008) Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane compo-nent-1. J. Clin. Endocrinol. Metab. 93, 1592-1599.
145. Xu, J., Zeng, C., Chu, W., Pan, F., and Rothfuss., J. M., Zhang, F., Tu, Z., Zhou, D., Zeng, D., Vangveravong, S., Johnston, F., Spitzer, D., Chang, K. C., Hotchkiss, R S., Hawkins, W. G, Wheeler, K. T., and Mach, R H. (2011) Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat. Commun. 2, 380.
146. Ahmed, I. S., Chamberlain, C., and Craven, R J. (2012) S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling. Expert Opin. Drug Metab. Toxicol. 8, 361-370.
147. Gerdes, D., Wehling, M., Leube, B., and Falkenstein, E. (1998) Cloning and tissue expression of two putative steroid membrane receptors. Biol. Chem. 379, 907-911.
148. Kimura, I., Nakayama, Y., Yamauchi, H, Konishi, M., Miyake, A., Mori, M., Ohta, M., Itoh, N, and Fujimoto, M. (2008) Neurotrophic activity of neudesin, a novel extracellular heme-binding protein, is dependent on the binding of heme to its cytochrome b5-like heme/steroid-binding domain. J. Biol. Chem. 283, 4323-4331.
149. Min, L., Takemori, H, Nonaka, Y., Katoh, Y., Doi, J., Horike, N, Osamu, H, and Raza., F. S., Vinson, G P., and Okamoto, M. (2004) Characterization of the adrenal-specific antigen IZA (inner zone antigen) and its role in the steroidogenesis. Mol. Cell. Endocrinol. 215, 143-148.
150. Szczesna-Skorupa, E., and Kemper, B. (2011) Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase. Mol. Pharmacol. 79, 340-350.
151. Oda, S., Nakajima, M., Toyoda, Y., Fukami, T., and Yokoi, T. (2011) Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner. Drug Metab. Dispos. 39, 2057-2065.
152. Rohe, H. J., and Ahmed., I. S., Twist, K E., and Craven, R J. (2009) PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol. Ther. 121, 14-19.
153. Kratz, F. (2014) A clinical update of using albumin as a drug vehicle - a commentary. J. Controlled Release 190, 331-336.
154. Fanali, G., di Masi, A, Trezza, V, Marino, M., Fasano, M., and Ascenzi, P. (2012) Human serum albumin: from bench to bedside. Mol. Aspects Med. 33, 209-290.
155. Peters, J. T. (1996) All about Albumin: Biochemistry, Genetics, and Medical Applications, Academic Press, San Diego, CA.
156. Witke, W. F., and Gibbs., P. E., Zielinski, R., Yang, F., Bowman, B. H., and Dugaiczyk, A. (1993) Complete structure of the human Gc gene: differences and similarities between members of the albumin gene family. Genomics 16, 751-754.
157. Bowman, B. H. (1993) Hepatic Plasma Proteins: Mechanisms of Function and Regulation, Academic Press, San Diego, CA.
158. Poulin, P. (2013) Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: emphasis on an apparent fraction unbound in liver for drugs. J. Pharm. Sci. 102, 2085-2095.
159. (2004) Applications of Pharmacokinetic Principles In Drug Development (Krishna, R., ed.) Kluwer Academic/Plenum Press, New York.
160. Wattanachai, N., and Polasek., T. M., Heath, T. M., Uchaipichat, V., Tassaneeyakul, W., and Miners, J. O. (2011) In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur. J. Clin. Pharmacol. 67, 815-824.
161. Zhou, Q., Matsumoto, S., Ding, L. R., Fischer, N. E., and Inaba, T. (2004) The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. Life Sci. 75, 2145-2155.
162. Rowland, A., and Elliot., D. J., Knights, K. M., Mackenzie, P. I., and Miners, J. O. (2008) The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab. Dispos. 36, 870-877.
163. Wattanachai, N., Tassaneeyakul, W., Rowland, A., Elliot, D. J., Bowalgaha, K., Knights, K. M., and Miners, J. O. (2012) Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance. Drug Metab. Dispos. 40, 982-989.
164. Xu, B. Q., Ishii, M., Ding, L. R., Fischer, N. E., and Inaba, T. (2003) Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. Life Sci. 72, 1953-1962.
165. Ishii, M., and Xu., B. Q., Ding, L. R., Fischer, N. E., and Inaba, T. (2001) Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and alpha-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat. Toxicol. Lett. 119, 219-225.
166. Yamazaki, H., and Shimada, T. (1999) Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 29, 231-241.
167. Rowland, A., and Knights., K. M., Mackenzie, P. I., and Miners, J. O. (2009) Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metab. Dispos. 37, 1395-1403.
168. Metz, A., Ciglia, E., and Gohlke, H. (2012) Modulating protein-protein interactions: from structural determinants of binding to druggability prediction to application. Curr. Pharm. Des. 18, 4630-4647.